Bruker BioSciences Corporation to Present at Lehman Brothers Tenth Annual Global Healthcare Conference.

Live Webcast on Monday, March 19, 2007 at 3:15 PM Eastern Time from Miami

BILLERICA, Mass. -- Bruker BioSciences Corporation today announced that it will join other leading life sciences companies in presenting at the Lehman Brothers Tenth Annual Global Healthcare Conference taking place March 19-21, 2007 in Miami. Bruker BioSciences Corporation's Chief Financial Officer, William J. Knight, will present an overview of the Company.

Mr. Knight's presentation will be webcast live at 3:15 PM Eastern Time (12:15 PM Pacific Time) on Monday, March 19, 2007 from the Loews Miami Beach Hotel. The webcast can be accessed on Bruker BioSciences' website at www.bruker-biosciences.com with playback.

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis and spark-OES tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, and also offers a broad line of chemical, biological, radiological and nuclear (CBRN) detection products for homeland security. Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology. For more information, please visit www.bruker-biosciences.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our reorganization strategies, risks related to the integration of businesses we have acquired or may acquire in the future, technological approaches, product development, market acceptance, cost and pricing of our products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2005, our most recent quarterly reports on Form 10-Q, our S-3/A filed on January 29, 2007 and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.